Hints and tips:
...“While we remain constructive on the long-term growth opportunity for Monster Beverage and view the pending Coke deal as transformational, we now see more limited upside,” said Judy Hong, an analyst at Goldman...
...“We view the FDA’s response as encouraging and generally in line with our view that any regulatory outcome is likely to be benign,” Judy Hong, analyst at Goldman Sachs, wrote in a note to clients....
...“We underestimated the increased headline risk around regulatory and legal uncertainty in the near term,” Judy Hong, analyst at Goldman Sachs, wrote in a note....
International Edition